Spring Bk Pharms

SBPH NASDAQ
6.92
-0.03
-0.43%
After Hours: 6.92 0 0.00% 16:51 05/17 EDT
Open
6.90
Prev Close
6.95
High
7.36
Low
6.85
Volume
67.43K
Avg Vol (3M)
41.13K
52 Week High
15.00
52 Week Low
6.30
% Turnover
0.41%
Market Cap
113.79M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Spring Bk Pharms SBPH stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
MORE >

Recently

Name
Price
%Change